View source for Ganetespib (STA-9090)

==General information==
Class/mechanism: Small molecule inhibitor of Hsp90 (heat shock protein 90). Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, ganetespib is hypothesized to accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.<ref>[http://www.syntapharma.com/PrdHsp90.aspx Synta Pharmaceuticals' Ganetespib site]</ref><ref>Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011 Apr 14;6(4):e18552. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077378/ link to original article] [https://pubmed.ncbi.nlm.nih.gov/21533169/ PubMed]</ref>
<br>Route: IV 
<br>Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. 

==Patient drug information==
No information available.

==Also known as==
*'''Code name:''' STA-9090

==References==
<references/>

[[Category:Drugs]]

[[Category:Intravenous medications]]

[[Category:Hsp90 inhibitors]]

[[Category:Investigational drugs]]